LA JOLLA, Calif.—Early April saw MediciNova Inc. announce the early termination of its Phase 2 clinical trial of MN-001 in non-alcoholic steatohepatitis and non-alcoholic fatty liver disease with hypertriglyceridemia, due to positive results from the interim analysis. The compound significantly reduced mean serum triglycerides—a primary endpoint—from 260.1 mg/dL before treatment to 185.2 mg/dL after eight weeks of treatment, with no clinically significant safety or tolerability issues. MediciNova plans to accelerate development of MN-001 given these results.